FY2028 EPS Estimates for Inventiva S.A. (NASDAQ:IVA) Raised by Analyst

Inventiva S.A. (NASDAQ:IVA - Free Report) - Research analysts at HC Wainwright upped their FY2028 earnings per share estimates for shares of Inventiva in a research note issued to investors on Monday, April 1st. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of $2.45 per share for the year, up from their prior estimate of $2.43. HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Inventiva's current full-year earnings is ($2.23) per share.

Other equities analysts also recently issued reports about the company. Lifesci Capital restated an "outperform" rating on shares of Inventiva in a report on Friday, January 5th. Stifel Nicolaus dropped their price target on shares of Inventiva from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Friday, February 16th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $15.67.

Inventiva Price Performance

IVA traded up $0.01 during midday trading on Wednesday, reaching $3.64. The company's stock had a trading volume of 19,118 shares, compared to its average volume of 37,260. The stock's 50-day moving average is $3.72 and its 200-day moving average is $3.98. Inventiva has a 1 year low of $2.22 and a 1 year high of $5.05.

Institutional Investors Weigh In On Inventiva

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley lifted its holdings in Inventiva by 300.0% in the 4th quarter. Morgan Stanley now owns 6,000 shares of the company's stock worth $27,000 after purchasing an additional 4,500 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in shares of Inventiva in the first quarter valued at $51,000. Finally, Citigroup Inc. increased its holdings in shares of Inventiva by 91.7% in the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company's stock worth $84,000 after buying an additional 11,000 shares during the last quarter. Institutional investors own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.